On top of that, it has ramped up its merger and acquisitions (M&A) activity to create new growth drivers for the future. Pfizer reported another solid quarter driven by its dotbig review two cash cows. Investors’ concerns surrounding its future are valid, but the ramp-up in merger and acquisitions activity bodes well for PFE stock’s long-term prospects.
Please log in to your account or sign up in order to add this asset to your watchlist. http://dotbig.com/markets/stocks/PFE/ Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
Represents the company’s profit divided by the outstanding shares of its common stock. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. But if Pfizer has strength, it will not allow this short-term Pfizer stock price moving average to break it below a longer-term moving average, that being the 50-week. Turning to Wall Street, PFE has a Moderate Buy consensus rating based on five Buys and eight Holds assigned in the past three months. The average PFE price target of $57.42 implies 15.8% upside potential.
- Comirnaty and Paxlovid have generated massive sales for the company and continue contributing immensely to total revenues.
- Eliquis revenue was up 23%, while Prevnar sales grew 18% in Q2.
- The Motley Fool has no position in any of the stocks mentioned.
- Please log in to your account or sign up in order to add this asset to your watchlist.
- Our dashboard on Pfizer revenues has details of the company’s segments.
Learn about financial terms, types of investments, trading strategies and more. 358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company’s employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Pfizer is 8.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 82.50. MarketBeat has tracked 20 news articles for Pfizer this week, compared to 30 articles on an average week.
Svb Securities Sticks To Their Hold Rating For Pfizer Pfe
Further, Paxlovid is another innovative game changer, even though “rebound cases” or “Paxlovid rebounds” have caused many to view the drug in a less favorable light. Nevertheless, it’s not just Pfizer’s pipeline that has me intrigued as it looks to keep growth alive in the latter part of the decade. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within dotbig forex the next days. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Biotechnology is the scientific study using living organisms to develop healthcare products and processes.
It should be able to piggy-bank over the success of its two growth drivers and usher in the next era of growth. The company’s free cash flow in 2021 came in at a tremendous $29.9 billion compared to $10.5 billion in 2019. Hence, it’s clear that the company has enough money to fund its shopping spree. It started off its spree with an early-stage Forex news biotech, Trillium Therapeutics, which develops drugs to fight hematological cancers. The CIP is a direct stock purchase and dividend reinvestment plan administered by Computershare Trust Company, N.A., not by Pfizer. Be sure to include your name, address, daytime phone number, account number, company name on all correspondence.
Pfizer’s recent acquisition of migraine firm Biohaven Pharmaceuticals is an interesting deal, especially at a modest $12 billion price tag. Though patent losses are bound to happen over the coming years, Pfizer can more than offset such woes with newly-acquired drugs . Moderna seems incredibly confident that its shares are undervalued, and they may very well be, as the COVID-19 pandemic https://dotbig.com/ could pave the way for robust demand through year’s end. Currently, the BA.4 and BA.5 variants of Omicron could pose issues in the latter part of the year. Undoubtedly, the world is less likely to lockdown should such variants spark outbreaks, given the economic damage that could ensue. More boosters in arms are vital to adapting in the COVID-19 era and living with the horrific disease.
Latest On Pfizer Inc
Pfizer is ready to innovate so that it can thrive in an environment where its COVID-19 business sees sales dwindle to zero. Pfizer is a wonderful company I’ve previously described as https://www.forex.com/ one of the market’s most innovative. The company was first to unveil a safe and effective COVID-19 vaccine back in 2021 — a breakthrough that many of us have now taken for granted.
What You Need To Know About Investing In Pfizer
Still, just because things are the most “normal” they’ve been in this pandemic does not mean COVID-19 isn’t out there. Come the fall season, new variants are likely to return, and that could accompany robust demand for booster shots. Going into a recession or slowdown, biopharma stocks should be in high demand. As one of the best-managed ones out there, is more than deserving of a premier multiple. Research indicates that these estimate revisions are directly correlated with near-term share price momentum.
Pfizer Inc Past Events
Furthermore, Prevnar, which is its pneumococcal vaccine, posted $1.4 billion in sales, up 18%. Its kidney cancer and heart disease drugs have also registered double-digit growth from the same period last year. dotbig website Furthermore, given its rock-solid second-quarter results, it seems that top and bottom-line expansion won’t stop anytime soon. It has time to continue milking its two cash cows to generate strong numbers.
On Dec. 11, 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine to receive emergency use authorization from the U.S. The vaccine was approved for emergency use for individuals 16 years of age and older. Pfizer develops, manufactures, and distributes biopharmaceutical products to treat and cure a range of diseases. Pfizer has become one of the biggest pharmaceutical companies in http://dotbig.com/markets/stocks/PFE/ the world, with a market capitalization of $251.3 billion as of Nov. 3, 2021. Perhaps the major concern for long-term investors of Pfizer is its future. A lot has been made of how the business could survive once its two primary growth drivers phase out in popularity. The firm’s management seems to be more proactive in its attempt to create more income streams by boosting its M&A activity.
Leave A Comment